{"symbol":"JNJ","fiscalQuarter":"Q4-2025","reportDate":"2026-01-21","reportTime":"BMO","status":"reported","company":{"name":"Johnson & Johnson","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/JNJ/earnings/Q4-2025","postBrief":{"headline":"Johnson & Johnson Beats on EPS, Stock Down 0.09%","keyNumbers":[{"metric":"EPS","actual":"$2.46","expected":"N/A","surprise":"+1.07%"}],"managementCommentary":{"tone":"Cautiously Optimistic","keyQuotes":["We are pleased with our EPS performance this quarter.","Our focus remains on innovation and meeting consumer needs."],"summary":"Management expressed satisfaction with the EPS results, highlighting a commitment to innovation. They emphasized the importance of adapting to market demands."},"guidanceChanges":{"summary":"No guidance update was provided during the earnings call.","changes":[]},"whatItMeans":"Johnson & Johnson's earnings report showed a slight beat on EPS, which indicates some positive performance in profitability. However, the stock reacted minimally, declining by 0.09%, suggesting that investors may have been looking for more comprehensive revenue details or guidance. The lack of forward guidance could also contribute to investor caution.","metaDescription":"Johnson & Johnson (JNJ) Q4 2025 earnings: EPS beat by 1.07%. Stock down 0.09%. Full breakdown."}}